About: Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer. It also offers CHOICE, a technology and discovery and development platform; and developed an extensive library of isolated and engineered oncolytic VACV immunotherapeutic product candidates. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Sector: Healthcare
Industry: Biotechnology
Latest price: $2.17 (-2.04%)
GNLX NASDAQ Genelux Corporation Common Stock
Genelux Corporation Common Stock share price
Atividade de preço de GNLX
Último preço
$ 2,170
Variação (24h)
-0,05 USD (2,04%)
Volume
19.21K
Volume (média 4 sem.)
-
Abertura
$ 2,19
Variação do dia
$ 2,13 - $ 2,20
Fechamento anterior
$ 2,21
Último negócio
29 Oct, 2:14 pm GMT+0
Atrasado
29 Oct, 2:14 pm GMT+0
GNLX price performance
Atrasado
29 Oct, 2:14 pm GMT+0
quote.marketSignals